BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xiao G, Jin LL, Liu CQ, Wang YC, Meng YM, Zhou ZG, Chen J, Yu XJ, Zhang YJ, Xu J, Zheng L. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. J Immunother Cancer. 2019;7:300. [PMID: 31727135 DOI: 10.1186/s40425-019-0784-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
Number Citing Articles
1 Sanceau J, Gougelet A. Epigenetic mechanisms of liver tumor resistance to immunotherapy. World J Hepatol 2021; 13(9): 979-1002 [PMID: 34630870 DOI: 10.4254/wjh.v13.i9.979] [Reference Citation Analysis]
2 Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O'Byrne K, Rezaei N, Kulasinghe A. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev 2021;41:1474-98. [PMID: 33277742 DOI: 10.1002/med.21765] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
3 Zhou G, Boor PPC, Bruno MJ, Sprengers D, Kwekkeboom J. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. Br J Cancer 2021. [PMID: 34400801 DOI: 10.1038/s41416-021-01453-3] [Reference Citation Analysis]
4 Jin Y, Zuo HX, Li MY, Zhang ZH, Xing Y, Wang JY, Ma J, Li G, Piao H, Gu P, Jin X. Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo. Front Pharmacol 2021;12:774231. [PMID: 34899336 DOI: 10.3389/fphar.2021.774231] [Reference Citation Analysis]
5 He Q, Liu M, Huang W, Chen X, Zhang B, Zhang T, Wang Y, Liu D, Xie M, Ji X, Sun M, Tian D, Xia L. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1. Hepatology 2021. [PMID: 34288020 DOI: 10.1002/hep.32062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kang N, Eccleston M, Clermont PL, Latarani M, Male DK, Wang Y, Crea F. EZH2 inhibition: a promising strategy to prevent cancer immune editing. Epigenomics 2020;12:1457-76. [PMID: 32938196 DOI: 10.2217/epi-2020-0186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Zhu J, Zhu N, Xu J. miR‑101a‑3p overexpression prevents acetylcholine‑CaCl2‑induced atrial fibrillation in rats via reduction of atrial tissue fibrosis, involving inhibition of EZH2. Mol Med Rep 2021;24:740. [PMID: 34435649 DOI: 10.3892/mmr.2021.12380] [Reference Citation Analysis]
8 Jiao J, Sanchez JI, Thompson EJ, Mao X, McCormick JB, Fisher-Hoch SP, Futreal PA, Zhang J, Beretta L. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics. Int J Mol Sci 2021;22:7411. [PMID: 34299031 DOI: 10.3390/ijms22147411] [Reference Citation Analysis]
9 Yadollahi P, Jeon YK, Ng WL, Choi I. Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity. BMB Rep 2021;54:12-20. [PMID: 33298250 [PMID: 33298250 DOI: 10.5483/bmbrep.2021.54.1.241] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wu BK, Chen QH, Pan D, Chang B, Sang LX. A novel therapeutic strategy for hepatocellular carcinoma: Immunomodulatory mechanisms of selenium and/or selenoproteins on a shift towards anti-cancer. Int Immunopharmacol 2021;96:107790. [PMID: 34162153 DOI: 10.1016/j.intimp.2021.107790] [Reference Citation Analysis]
11 Pyziak K, Sroka-Porada A, Rzymski T, Dulak J, Łoboda A. Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation. Drug Dev Res 2021;82:730-53. [PMID: 33565092 DOI: 10.1002/ddr.21796] [Reference Citation Analysis]
12 Garcia-Lacarte M, Grijalba SC, Melchor J, Arnaiz-Leché A, Roa S. The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. Cancers (Basel) 2021;13:4683. [PMID: 34572910 DOI: 10.3390/cancers13184683] [Reference Citation Analysis]
13 Bugide S, Gupta R, Green MR, Wajapeyee N. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. Proc Natl Acad Sci U S A 2021;118:e2102718118. [PMID: 34301901 DOI: 10.1073/pnas.2102718118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Kumar S, Sarthi P, Mani I, Ashraf MU, Kang MH, Kumar V, Bae YS. Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. Cells 2021;10:2250. [PMID: 34571899 DOI: 10.3390/cells10092250] [Reference Citation Analysis]
15 Glorieux C, Xia X, Huang P. The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer. Cancers (Basel) 2021;13:4426. [PMID: 34503236 DOI: 10.3390/cancers13174426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Feng Y, Dramani Maman ST, Zhu X, Liu X, Bongolo CC, Liang C, Tu J. Clinical value and potential mechanisms of LINC00221 in hepatocellular carcinoma based on integrated analysis. Epigenomics 2021;13:299-317. [PMID: 33406920 DOI: 10.2217/epi-2020-0363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol 2021;14:10. [PMID: 33413496 DOI: 10.1186/s13045-020-01027-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]
18 Li Z, Sun G, Sun G, Cheng Y, Wu L, Wang Q, Lv C, Zhou Y, Xia Y, Tang W. Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges. Front Oncol 2021;11:771335. [PMID: 34869005 DOI: 10.3389/fonc.2021.771335] [Reference Citation Analysis]
19 Huang J, Zhang J, Guo Z, Li C, Tan Z, Wang J, Yang J, Xue L. Easy or Not-The Advances of EZH2 in Regulating T Cell Development, Differentiation, and Activation in Antitumor Immunity. Front Immunol 2021;12:741302. [PMID: 34737746 DOI: 10.3389/fimmu.2021.741302] [Reference Citation Analysis]
20 Wang X, Liang C, Yao X, Yang RH, Zhang ZS, Liu FY, Li WQ, Pei SH, Ma J, Xie SQ, Fang D. PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC. Front Pharmacol 2020;11:577108. [PMID: 33324209 DOI: 10.3389/fphar.2020.577108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Yang S, Lin S, Liu K, Liu Y, Xu P, Zheng Y, Deng Y, Zhang D, Zhai Z, Li N, Ren X, Dai Z, Kang H. Identification of an immune-related RNA-binding protein signature to predict survival and targeted therapy responses in liver cancer. Genomics 2021;113:795-804. [PMID: 33524497 DOI: 10.1016/j.ygeno.2021.01.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wei Y, Xiao X, Lao XM, Zheng L, Kuang DM. Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cell Mol Life Sci 2021;78:867-87. [PMID: 32940722 DOI: 10.1007/s00018-020-03637-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Nagaraju GP, Malla RR, Basha R, Motofei IG. Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1. Semin Cancer Biol 2021:S1044-579X(21)00270-4. [PMID: 34774995 DOI: 10.1016/j.semcancer.2021.11.003] [Reference Citation Analysis]
24 Hong S, Li S, Bi M, Yu H, Yan Z, Liu T, Wang H. lncRNA ILF3-AS1 promotes proliferation and metastasis of colorectal cancer cells by recruiting histone methylase EZH2. Mol Ther Nucleic Acids 2021;24:1012-23. [PMID: 34141456 DOI: 10.1016/j.omtn.2021.04.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Hudson K, Cross N, Jordan-Mahy N, Leyland R. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Front Immunol. 2020;11:568931. [PMID: 33193345 DOI: 10.3389/fimmu.2020.568931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Gan X, Luo Y, Dai G, Lin J, Liu X, Zhang X, Li A. Identification of Gene Signatures for Diagnosis and Prognosis of Hepatocellular Carcinomas Patients at Early Stage. Front Genet 2020;11:857. [PMID: 32849835 DOI: 10.3389/fgene.2020.00857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021; 13(7): 795-824 [PMID: 34367478 DOI: 10.4252/wjsc.v13.i7.795] [Reference Citation Analysis]
28 Zhang H, Xia P, Ma W, Yuan Y. Development and Validation of an RNA Binding Protein-associated Prognostic Model for Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:635-46. [PMID: 34722178 DOI: 10.14218/JCTH.2020.00103] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng WJ, Liu Z, Cheng Q. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res 2021;40:184. [PMID: 34088360 DOI: 10.1186/s13046-021-01987-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
30 Bhat KP, Ümit Kaniskan H, Jin J, Gozani O. Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov 2021;20:265-86. [PMID: 33469207 DOI: 10.1038/s41573-020-00108-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
31 Feng H, Zhang YB, Gui JF, Lemon SM, Yamane D. Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses. PLoS Pathog 2021;17:e1009220. [PMID: 33476326 DOI: 10.1371/journal.ppat.1009220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
32 Li C, Wang Y, Gong Y, Zhang T, Huang J, Tan Z, Xue L. Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors. Clin Epigenetics 2021;13:62. [PMID: 33761979 DOI: 10.1186/s13148-021-01045-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Wang L, Zhou N, Qu J, Jiang M, Zhang X. Identification of an RNA binding protein-related gene signature in hepatocellular carcinoma patients. Mol Med 2020;26:125. [PMID: 33297932 DOI: 10.1186/s10020-020-00252-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Perrier A, Didelot A, Laurent-Puig P, Blons H, Garinet S. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. Biomolecules 2020;10:E1061. [PMID: 32708698 DOI: 10.3390/biom10071061] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
35 Zhang G, Chen X, Ma L, Ding R, Zhao L, Ma F, Deng X. LINC01419 facilitates hepatocellular carcinoma growth and metastasis through targeting EZH2-regulated RECK. Aging (Albany NY) 2020;12:11071-84. [PMID: 32522890 DOI: 10.18632/aging.103321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Turkes F, Mencel J, Starling N. Targeting the immune milieu in gastrointestinal cancers. J Gastroenterol 2020;55:909-26. [PMID: 32748171 DOI: 10.1007/s00535-020-01710-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Tao H, Liu M, Wang Y, Luo S, Xu Y, Ye B, Zheng L, Meng K, Li L. Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation. Front Immunol 2021;12:609295. [PMID: 33717093 DOI: 10.3389/fimmu.2021.609295] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Li J, Du S, Shi Y, Han J, Niu Z, Wei L, Yang P, Chen L, Tian H, Gao L. Rapamycin ameliorates corneal injury after alkali burn through methylation modification in mouse TSC1 and mTOR genes. Exp Eye Res 2021;203:108399. [PMID: 33352197 DOI: 10.1016/j.exer.2020.108399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Yan Q, Zheng W, Wang B, Ye B, Luo H, Yang X, Zhang P, Wang X. A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma. BioData Min 2021;14:29. [PMID: 33962640 DOI: 10.1186/s13040-021-00261-y] [Reference Citation Analysis]
40 McGoverne I, Dunn J, Batham J, Tu WJ, Chrisp J, Rao S. Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response. BMC Immunol 2020;21:22. [PMID: 32316916 DOI: 10.1186/s12865-020-00353-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
41 Abhimanyu, Ontiveros CO, Guerra-Resendez RS, Nishiguchi T, Ladki M, Hilton IB, Schlesinger LS, DiNardo AR. Reversing Post-Infectious Epigenetic-Mediated Immune Suppression. Front Immunol 2021;12:688132. [PMID: 34163486 DOI: 10.3389/fimmu.2021.688132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Tian S, Liu J, Sun K, Liu Y, Yu J, Ma S, Zhang M, Jia G, Zhou X, Shang Y, Han Y. Systematic Construction and Validation of an RNA-Binding Protein-Associated Model for Prognosis Prediction in Hepatocellular Carcinoma. Front Oncol 2020;10:597996. [PMID: 33575212 DOI: 10.3389/fonc.2020.597996] [Reference Citation Analysis]
43 Chen S, Zhao E. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;45:101587. [PMID: 33662631 DOI: 10.1016/j.clinre.2020.101587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Lang X, Chen Z, Yang X, Yan Q, Xu M, Liu W, He Q, Zhang Y, Cheng W, Zhao W. Scutellarein induces apoptosis and inhibits proliferation, migration, and invasion in ovarian cancer via inhibition of EZH2/FOXO1 signaling. J Biochem Mol Toxicol 2021;:e22870. [PMID: 34350670 DOI: 10.1002/jbt.22870] [Reference Citation Analysis]
45 Feng S, De Carvalho DD. Clinical advances in targeting epigenetics for cancer therapy. FEBS J. [DOI: 10.1111/febs.15750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Teng CF, Li TC, Wang T, Wu TH, Wang J, Wu HC, Shyu WC, Su IJ, Jeng LB. Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant. J Hepatocell Carcinoma 2020;7:385-401. [PMID: 33365286 DOI: 10.2147/JHC.S282818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Vaziri F, Colquhoun S, Wan YY. Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome. Liver Res 2020;4:191-8. [PMID: 33343967 DOI: 10.1016/j.livres.2020.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]